Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TATCIST: FPI-2265 in mCRPC
NCT05219500Phase 2Active, not recruiting
- Sponsor
- Fusion Pharmaceuticals Inc.
- Start
- Dec 2021
- Primary completion
- May 2025
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of actinium-225 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Fusion Pharmaceuticals Inc. Primary endpoint: Prostate-Specific Antigen Effect at 12 weeks. Started Dec 2021; status: active, not recruiting.
02
Drugs
actinium-225 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05219500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05219500.